Next Generation Immunotherapies Market Report 2026

Next Generation Immunotherapies Market Overview

• Next Generation Immunotherapies market size has reached to $150.12 billion in 2025 • Expected to grow to $262.82 billion in 2030 at a compound annual growth rate (CAGR) of 11.8% • Growth Driver: Rising Cancer Prevalence Driving Growth In The Market • Market Trend: Innovative CAR T-Cell Therapy Revolutionizes Cancer Treatment In India • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Next Generation Immunotherapies Market?

Next-generation immunotherapies refer to advanced treatments designed to enhance the body's immune system to fight diseases, particularly cancer, with improved precision, efficacy, and safety. These therapies go beyond traditional immune-based treatments by leveraging cutting-edge technologies and aim to overcome earlier immunotherapies' limitations, reduce side effects, and offer long-lasting immune responses. The main drug classes in the next-generation immunotherapies are monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are lab-engineered proteins designed to precisely target specific antigens, enhancing immune response and treatment effectiveness. These drugs are administered through various routes, including intravenous, parenteral, intratumoral, subcutaneous, and oral. They are distributed through multiple channels, such as hospital pharmacies, clinical pharmacies, and other distribution channels.

What Is The Next Generation Immunotherapies Market Growth Forecast?

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $262.82 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in next-generation antibody engineering, expanding applications beyond oncology, increasing approval of adc-based therapies, growth in biomarker-driven treatment selection, rising demand for durable and long-lasting therapies. Major trends in the forecast period include expansion of combination immunotherapy regimens, growth in personalized cancer vaccines, rising adoption of bispecific antibodies, increasing focus on reducing immune-related adverse events, accelerated clinical trial activity in solid tumors.

Global Next Generation Immunotherapies Market Segmentation

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors 2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral 3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels Subsegments: 1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies 2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs 3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications 4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

What Is The Driver Of The Next Generation Immunotherapies Market?

The increasing prevalence of cancer is expected to propel the growth of the next-generation immunotherapies market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The prevalence of cancer is due to factors such as aging populations, lifestyle changes, environmental exposures, and improved detection methods. Next-generation immunotherapies provide advanced, targeted treatments that enhance the body's immune response to cancer, offering greater effectiveness, durability, and personalization. For instance, in July 2024, according to the projections published by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are projected to increase for most types between 2023-2025 and 2038-2040, with rises ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller number of cancers are expected to see a decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Therefore, the increasing prevalence of cancer is driving the growth of next-generation immunotherapies market.

Key Players In The Global Next Generation Immunotherapies Market

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Global Next Generation Immunotherapies Market Trends and Insights

Major companies operating in the next-generation immunotherapies market are focusing on developing innovative therapies, such as CAR T-cell therapy, to treat cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is a type of immunotherapy where a patient's T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, launched Qartemi, an India's first CAR T-cell therapy. This therapy is for adult B-cell non-Hodgkin lymphoma, genetically modifying a patient's immune cells to target and destroy cancer cells, offering a highly effective and personalized treatment option. It provides renewed hope to patients for whom conventional treatments have proven ineffective, with the advantage of being more affordable than similar global options.

What Are Latest Mergers And Acquisitions In The Next Generation Immunotherapies Market?

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. With this acquisition, Coherus BioSciences aims to expand its immuno-oncology portfolio by introducing novel therapies that target the tumor microenvironment to enhance cancer treatment. Surface Oncology Inc. is a US-based immuno-oncology (I-O) company that focuses on developing next-generation immunotherapies designed to target the tumor microenvironment.

Regional Outlook

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Next Generation Immunotherapies Market?

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Next Generation Immunotherapies Market Report 2026?

The next generation immunotherapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the next generation immunotherapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.